NPM1-mutations are well-documented in de novo AML, therapy-related AML, and also in donor cell-derived AML, supporting that NPM1 mutations are founder genetic alterations defining an independent AML entity [4,5]. Here, NPM1 is linked to acute myeloid leukemia.